Pdl Biopharma, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Cash Flow Guidance for the Period from 2018-2022
For the six months, the company reported total revenues were $85,093,000 compared to $189,275,000 a year ago. Operating loss was $120,834,000 compared to income of $131,285,000 a year ago. Loss before income taxes was $123,940,000 compared to income of $128,058,000 a year ago. Net loss was $110,694,000 compared to income of $67,633,000 a year ago. Net loss attributable to company shareholders was $110,694,000 compared to income of $67,680,000 a year ago. Loss of $0.74 per basic and diluted share compared to income of $0.42 per basic and diluted share a year ago. Non-GAAP net income was $29,511,000 compared to $50,250,000 a year.
The company provided cash flow guidance for the period from 2018-2022. For the period, the company expected cash flow to exceed $400 million in cash through 2018 to 2022.